


**CLAIM AMENDMENTS****Listing of Claims:**

1-14. (Cancelled)

15. (Currently Amended) A method for treating a patient suffering from chronic inflammation comprising administering to said patient an effective amount of a benzimidazole compound of formula II



or a physiologically compatible salt thereof,

in which

$R^1$  means a monocyclic or bicyclic  $C_{6-12}$  aryl group optionally substituted with up to three of the following substituents, independently of one another selected from: F, Cl, Br, I,  $C(NH)NH_2$ ,  $C(NH)NHR^4$ ,  $C(NH)NR^4R^4$ ,  $C(NR^4)NH_2$ ,  $C(NR^4)NHR^4$ ,  $C(NR^4)NR^4R^4$ ,  $XOH$ ,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOH)R^4$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ ,  $XCN$ ,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^4$ ,  $XCONHR^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,  $XNH_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,  $XNHSO_2R^4$ ,  $XN(SO_2R^4)(SO_2R^4)$ ,  $XNR^4SO_2R^4$ ,  $XNHCO_2R^4$ ,  $XNHCOOR^4$ ,  $XNHCONHR^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $R^4$ , [;]

$R^2$  means a monocyclic or bicyclic  $C_{6-10}$  aryl group optionally substituted with up to three of the following substituents, independently of one another selected from: F, Cl, Br, I,  $C(NH)NH_2$ ,  $C(NH)NHR^4$ ,  $C(NH)NR^4R^4$ ,  $C(NR^4)NH_2$ ,  $C(NR^4)NHR^4$ ,  $C(NR^4)NR^4R^4$ ,  $XOH$ ,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOH)R^4$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ ,  $XCN$ ,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^4$ ,  $XCONHR^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,

$\text{XSOR}^4$ ,  $\text{XSO}_2\text{R}^4$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NHR}^4$ ,  $\text{SO}_2\text{NR}^4\text{R}^4$ ,  $\text{NO}_2$ ,  $\text{XNH}_2$ ,  $\text{XNHR}^4$ ,  $\text{XNR}^4\text{R}^4$ ,  $\text{XNH}\text{SO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4)$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4$ ,  $\text{XNH}\text{COR}^4$ ,  $\text{XNH}\text{COOR}^4$ ,  $\text{XNH}\text{CONHR}^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $\text{R}^4$ , [[ $\frac{1}{2}$ ]]

$\text{R}^3$  stands for one or two substituents which are each independently of one another selected from:

hydrogen, F, Cl, Br, I,  $\text{XOH}$ ,  $\text{XOR}^4$ ,  $\text{XOCOR}^4$ ,  $\text{XOCONHR}^4$ ,  $\text{XOCOOR}^4$ ,  $\text{XCOR}^4$ ,  $\text{XC}(\text{NOH})\text{R}^4$ ,  $\text{XC}(\text{NOR}^4)\text{R}^4$ ,  $\text{XC}(\text{NO}(\text{COR}^4))\text{R}^4$ ,  $\text{XCN}$ ,  $\text{XCOOH}$ ,  $\text{XCOOR}^4$ ,  $\text{XCONH}_2$ ,  $\text{XCONHR}^4$ ,  $\text{XCONR}^4\text{R}^4$ ,  $\text{XCONHOH}$ ,  $\text{XCONHOR}^4$ ,  $\text{XCOSR}^4$ ,  $\text{XSR}^4$ ,  $\text{XSOR}^4$ ,  $\text{XSO}_2\text{R}^4$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NHR}^4$ ,  $\text{SO}_2\text{NR}^4\text{R}^4$ ,  $\text{NO}_2$ ,  $\text{XNH}_2$ ,  $\text{XNHR}^4$ ,  $\text{XNR}^4\text{R}^4$ ,  $\text{XNH}\text{SO}_2\text{R}^4$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4)$ ,  $\text{XNH}\text{COR}^4$ ,  $\text{XNH}\text{COOR}^4$ ,  $\text{XNH}\text{CONHR}^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, or 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $\text{R}^4$ , [[ $\frac{1}{2}$ ]]

$\text{R}^4$  and  $\text{R}^4$ , independently of one another, mean  $\text{C}_{1-4}$  perfluoroalkyl,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{2-6}$  alkynyl,  $\text{C}_{3-7}$  cycloalkyl, ( $\text{C}_{1-3}$  alkyl- $\text{C}_{3-7}$  cycloalkyl),  $\text{C}_{1-3}$  alkyl- $\text{C}_{6-10}$  aryl,  $\text{C}_{1-3}$  alkyl-5 to 10-membered heteroaryl with 1-4 heteroatoms selected from N, S and O,  $\text{C}_{6-10}$  aryl, or 5- to 10-membered heteroaryl with 1-4 heteroatoms selected from N, S and O atoms,

wherein the  $\text{C}_{6-10}$  aryl and heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl, Br,  $\text{CH}_3$ ,  $\text{C}_2\text{H}_5$ ,  $\text{NO}_2$ ,  $\text{OCH}_3$ ,  $\text{OC}_2\text{H}_5$ ,  $\text{CF}_3$ , and  $\text{C}_2\text{F}_5$ , or optionally carry an annelated methanediylbisoxy group or ethane-1,2-diylbisoxy group, and wherein a 5-membered cycloalkyl ring optionally has an N or O ring member, and wherein a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with  $\text{C}_{1-3}$  alkyl or  $\text{C}_{1-3}$  alkanoyl,

$\text{R}^5$  and  $\text{R}^5$ , independently of one another, mean hydrogen,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{2-6}$  alkynyl,

wherein in each case a carbon atom is optionally replaced by O, S, SO,  $\text{SO}_2$ , NH, N  $\text{C}_{1-3}$  alkyl or N  $\text{C}_{1-3}$  alkanoyl,  $\text{C}_{3-7}$  cycloalkyl- $\text{C}_{0-3}$  alkyl, wherein a 5-membered cycloalkyl ring optionally has an N or O ring member and a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O,

wherein ring nitrogens optionally are substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, C<sub>6-10</sub> aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms selected from N, S, and O, wherein the mentioned alkyl, alkenyl and alkynyl groups are optionally substituted with one of the previously mentioned cycloalkyls, aryls or heteroaryls, wherein all previously mentioned alkyl and cycloalkyl radicals are optionally substituted with up to two substituents selected from CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, OH, O C<sub>1-3</sub> alkyl, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, N(C<sub>1-3</sub> alkyl)(C<sub>1-3</sub> alkanoyl), COOH, CONH<sub>2</sub>, and COO C<sub>1-3</sub> alkyl, and all previously mentioned aryl and heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub> or optionally carry an annelated methanediylbisoxo, or ethane-1,2-diylbisoxo group, or

R<sup>5</sup> and R<sup>5'</sup> together with the nitrogen atom form a 5-to 7-membered group, which optionally contains another oxygen, nitrogen or sulfur atom and is optionally substituted by C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>0-2</sub> alkyl, C<sub>1-4</sub> alkoxy-carbonyl, aminocarbonyl or phenyl,

A means C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), (C<sub>0-5</sub> alkanediylarylene-C<sub>0-5</sub> alkanediyl), or (C<sub>0-5</sub> alkanediyl-heteroarylene-C<sub>0-5</sub> alkanediyl),

wherein the aryl and heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub>, wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl,

wherein in the mentioned aliphatic groups, one or two carbon atoms are each optionally replaced by O, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, or NSO<sub>2</sub>R<sup>4</sup>,

and wherein alkyl or cycloalkyl groups are optionally substituted with up to two substituents selected from F, OH, OR<sup>4</sup>, OCOR<sup>4</sup>, =O, NH<sub>2</sub>, NR<sup>4</sup>R<sup>4'</sup>, NHCOR<sup>4</sup>, NHCOOR<sup>4</sup>, NHCONHR<sup>4</sup>, NHSO<sub>2</sub>R<sup>4</sup> SH, and SR<sup>4</sup>,

B means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COR<sup>5</sup>, C(NOHR<sup>5</sup>),

- C(NOR<sup>5</sup>)R<sup>5'</sup>, C(NO(COR<sup>5</sup>))R<sup>5'</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHNH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>5</sup>, SO<sub>2</sub>NR<sup>5</sup>R<sup>5'</sup>, PO<sub>3</sub>H, PO(OH)(OR<sup>5</sup>), PO(OR<sup>5</sup>)(OR<sup>5'</sup>), PO(OH)(NHR<sup>5</sup>), PO(NHR<sup>5</sup>)(NHR<sup>5'</sup>), or tetrazolyl, each bonded to a carbon atom of group A,  
 or the entire group Y-A-B is N(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>) or NHSO<sub>2</sub>R<sup>4</sup>,
- X means a bond, CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>, CH(CH<sub>3</sub>), (CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>2</sub>CH<sub>3</sub>), CH(CH<sub>3</sub>)CH<sub>2</sub>, or CH<sub>2</sub>CH(CH<sub>3</sub>), and
- Y means a bond, O, S, SO, SO<sub>2</sub>, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, or NSO<sub>2</sub>R<sup>4</sup>.

16. (Currently Amended) A method according to claim 15, wherein  
 R<sup>1</sup> means a monocyclic or bicyclic aryl group optionally substituted with up to three of the following substituents, independently of one another selected from:  
 F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XCN, COOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONR<sup>4</sup>R<sup>4'</sup>, XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, NO<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>, ~~or~~ and R<sup>4</sup>.

17. (Currently Amended) A method according to claim 15, wherein,  
 R<sup>2</sup> means a monocyclic or bicyclic aryl group optionally substituted with up to three of the following substituents, independently of one another selected from:  
 F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONR<sup>4</sup>R<sup>4'</sup>, XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>), XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, ~~or~~ and R<sup>4</sup>.

18. (Previously Presented) A method according to claim 15, wherein  
 R<sup>3</sup> stands for one or two substituents, which independently of one another, each mean:  
 hydrogen, F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>,

XCN, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4'</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4'</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>), XNHCO<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, or R<sup>4</sup>.

19. (Previously Presented) A method according to claim 15, wherein R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-6</sub> cycloalkyl), C<sub>1-3</sub> alkylaryl, C<sub>1-3</sub> alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 heteroatoms selected from N, S and O, wherein the aryl and heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub>, or optionally carry an annelated methanediylbisoxo or ethane-1,2-diylbisoxo group, and wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl.
20. (Previously Presented) A method according to claim 15, wherein R<sup>5</sup> and R<sup>5'</sup>, independently of one another, are optionally C<sub>1-6</sub> alkyl wherein a carbon atom is optionally replaced by O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl, or C<sub>3-7</sub> cycloalkyl-C<sub>0-3</sub> alkyl, wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, wherein the mentioned C<sub>1-6</sub> alkyl group is optionally substituted with one of the previously mentioned cycloalkyls or a 5- to 6-membered heteroaromatic group with 1-2 heteroatoms selected from N, S and O, wherein all previously mentioned alkyl and cycloalkyl groups are optionally substituted with up to two substituents selected from CF<sub>3</sub>, OH, and O C<sub>1-3</sub> alkyl, and the previously mentioned heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl, CF<sub>3</sub>, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, OCH<sub>3</sub>, and OC<sub>2</sub>H<sub>5</sub>,

or R<sup>5</sup> and R<sup>5'</sup> together with the nitrogen atom form a 5- to 7-membered heterocyclic group which optionally contains another oxygen, nitrogen or sulfur atom and is optionally substituted by C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>0-2</sub> alkyl, C<sub>1-4</sub> alkoxy-carbonyl, aminocarbonyl or phenyl.

21. (Previously Presented) A method according to claim 15, wherein

A means C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), or (C<sub>0-5</sub> alkanediyl-heteroarylene-C<sub>0-5</sub> alkanediyl), wherein when a heteroaryl group is present it is optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub>, and wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, wherein in aliphatic groups one or two carbon atoms are optionally replaced by O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl, or NSO<sub>2</sub> C<sub>1-3</sub> alkyl, and wherein alkyl or cycloalkyl groups are optionally substituted with up to two F atoms or by one of the substituents selected from OH, O C<sub>1-3</sub> alkyl, O C<sub>1-3</sub> alkanoyl, =O, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl) (C<sub>1-3</sub> alkanoyl), NHCOO C<sub>1-3</sub> alkyl, NHCONH C<sub>1-3</sub> alkyl, NHSO<sub>2</sub> C<sub>1-3</sub> alkyl, SH, and S C<sub>1-3</sub> alkyl.

22. (Previously Presented) A method according to claim 15, wherein

B means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, or tetrazolyl, in each case bonded to a carbon atom of group A.

23. (Previously Presented) A method according to claim 15, wherein

X means a bond or CH<sub>2</sub>.

24. (Previously Presented) A method according to claim 15, wherein

Y means a bond, O, S, NH, NR<sup>4</sup>, NCOR<sup>4</sup> or NSO<sub>2</sub>R<sup>4</sup>.

25. (Cancelled)
26. (Previously Presented) A method according to claim 15, wherein said compound is  
6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy] hexanoic isopropyl ester.
27. (Cancelled)
28. (Cancelled)
29. (Currently Amended) A method according to claim 15, wherein  
 $R^1$  is a monocyclic or bicyclic aryl group optionally substituted with up to three of the following substituents, independently of one another selected from:  
F, Cl, Br, XOH,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ , XCN,  $COOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^4$ ,  $XCONHR^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $NO_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ , and  $R^4[\text{[ ]}]$ ;  
 $R^2$  means a monocyclic or bicyclic aryl group optionally substituted with up to three of the following substituents, independently of one another selected from:  
F, Cl, Br, XOH,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOHR^4)R^4$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ , XCN,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^4$ ,  $XCONHR^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,  $XNH_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,  $XNH(SO_2R^4)$ ,  $XN(SO_2R^4)(SO_2R^4)$ ,  $XNR^4SO_2R^4$ ,  $XNH(COR^4)$ ,  $XNH(COOR^4)$ ,  $XNHCONHR^4$ , and  $R^4[\text{[ ]}]$ ;  
 $R^3$  is one or two substituents, which independently of one another, each mean:  
hydrogen, F, Cl, Br, XOH,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOHR^4)R^4$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ , XCN,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,  $XNH_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,

$\text{XNH}\text{SO}_2\text{R}^4$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4)$ ,  $\text{XNH}\text{COR}^4$ ,  $\text{XNH}\text{COOR}^4$ ,  
 $\text{XNHCONHR}^4$ , or  $\text{R}^4$ ;

$\text{R}^4$  and  $\text{R}^4$ , independently of one another, mean  $\text{CF}_3$ ,  $\text{C}_2\text{F}_5$ ,  $\text{C}_{1-4}$  alkyl,  $\text{C}_{2-4}$  alkenyl,  $\text{C}_{2-4}$  alkynyl,  $\text{C}_{3-6}$  cycloalkyl, ( $\text{C}_{1-3}$  alkyl- $\text{C}_{3-6}$  cycloalkyl),  $\text{C}_{1-3}$  alkylaryl,  $\text{C}_{1-3}$  alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 heteroatoms selected from N, S and O, wherein the aryl and heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl, Br,  $\text{CH}_3$ ,  $\text{C}_2\text{H}_5$ ,  $\text{NO}_2$ ,  $\text{OCH}_3$ ,  $\text{OC}_2\text{H}_5$ ,  $\text{CF}_3$ , and  $\text{C}_2\text{F}_5$  or optionally carry an annelated methanediylbisoxo or ethane-1,2-diylbisoxo group, and wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with  $\text{C}_{1-3}$  alkyl or  $\text{C}_{1-3}$  alkanoyl;

$\text{R}^5$  and  $\text{R}^5$ , independently of one another, are  $\text{C}_{1-6}$  alkyl wherein a carbon atom is optionally replaced by O, NH, N  $\text{C}_{1-3}$  alkyl, N  $\text{C}_{1-3}$  alkanoyl, or  $\text{C}_{3-7}$  cycloalkyl- $\text{C}_{0-3}$  alkyl, wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with  $\text{C}_{1-3}$  alkyl or  $\text{C}_{1-3}$  alkanoyl, wherein the mentioned  $\text{C}_{1-6}$  alkyl group is optionally substituted with one of the previously mentioned cycloalkyls or a 5- to 6-membered heteroaromatic group with 1-2 heteroatoms selected from N, S and O,

wherein all previously mentioned alkyl and cycloalkyl groups are optionally substituted with up to two substituents selected from  $\text{CF}_3$ , OH, and O  $\text{C}_{1-3}$  alkyl, and the previously mentioned heteroaryl groups are optionally substituted with one or two substituents selected from F, Cl,  $\text{CF}_3$ ,  $\text{CH}_3$ ,  $\text{C}_2\text{H}_5$ ,  $\text{OCH}_3$ , and  $\text{OC}_2\text{H}_5$ , or  $\text{R}^5$  and  $\text{R}^5$  together with the nitrogen atom form a 5- to 7-membered heterocyclic group which optionally contains another oxygen, nitrogen or sulfur atom and is optionally substituted by  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  alkoxy- $\text{C}_{0-2}$  alkyl,  $\text{C}_{1-4}$  alkoxy-carbonyl, aminocarbonyl or phenyl;

A means  $\text{C}_{1-10}$  alkanediyl,  $\text{C}_{2-10}$  alkenediyl,  $\text{C}_{2-10}$  alkinediyl, ( $\text{C}_{0-5}$  alkanediyl- $\text{C}_{3-7}$

- cycloalkanediyl- $C_{0-5}$  alkanediyl), or ( $C_{0-5}$  alkanediyl-heteroarylene- $C_{0-5}$  alkanediyl), wherein when a heteroaryl group is present it is optionally substituted with one or two substituents selected from F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ , and  $C_2F_5$ , and wherein a 5-membered cycloalkyl ring optionally has a ring member selected from N and O, and a 6- or 7-membered cycloalkyl ring optionally has one or two ring members selected from N and O, wherein ring nitrogens optionally are substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl, wherein in aliphatic groups one or two carbon atoms are optionally replaced by O, NH, N  $C_{1-3}$  alkyl, N  $C_{1-3}$  alkanoyl, or  $NSO_2$   $C_{1-3}$  alkyl, and wherein alkyl or cycloalkyl groups are optionally substituted with up to two F atoms or by one of the substituents selected from OH, O  $C_{1-3}$  alkyl, O  $C_{1-3}$  alkanoyl, =O,  $NH_2$ , NH  $C_{1-3}$  alkyl, N ( $C_{1-3}$  alkyl) $_2$ , NH  $C_{1-3}$  alkanoyl, N ( $C_{1-3}$  alkyl) ( $C_{1-3}$  alkanoyl),  $NHCOO$   $C_{1-3}$  alkyl,  $NHCONH$   $C_{1-3}$  alkyl,  $NHSO_2$   $C_{1-3}$  alkyl, SH, and S  $C_{1-3}$  alkyl;
- B means hydrogen, OH,  $OCOR^5$ ,  $OCONHR^5$ ,  $OCOOR^5$ , COOH,  $COOR^5$ ,  $CONH_2$ ,  $CONHR^5$ ,  $CONR^5R^5$ ,  $CONHOH$ ,  $CONHOR^5$ , or tetrazolyl, in each case bonded to a carbon atom of group A;
- X means a bond or  $CH_2$ ; and
- Y means a bond, O, S, NH,  $NR^4$ ,  $NCOR^4$  or  $NSO_2R^4$ .


30. (Previously Presented) A method according to claim 15, wherein
- (a) in  $R^1$ ,  $R^2$  said aryl groups are substituted or unsubstituted phenyl, biphenyl, naphthyl, indane, or fluorenyl; and
- (b) in  $R^4$ ,  $R^{4'}$ ,  $R^5$  and  $R^{5'}$ , said aryl groups are substituted or unsubstituted phenyl, biphenyl, naphthyl, indane, or fluorenyl, and said heteroaryl group are substituted or unsubstituted pyrrolyl, thienyl, furanyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, furazanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienoimidazolyl, indolyl, isoindolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, indazolyl, imidazopyridinyl, purinyl, quinolyl, isoquinolyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl or pteridinyl.

31. (Cancelled)

32. (Previously Presented) A method according to claim 15, wherein
- $R^1$  is a monocyclic or bicyclic  $C_{6-12}$  aryl group which is unsubstituted or is substituted with up to three of the following substituents, independently of one another selected from:
- F, Cl, Br, I,  $C(NH)NH_2$ ,  $C(NH)NHR^4$ ,  $C(NH)NR^4R^4$ ,  $C(NR^4)NH_2$ ,  $C(NR^4)NHR^4$ ,  $C(NR^4)NR^4R^4$ ,  $XOH$ ,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOHR^4)$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ ,  $XCN$ ,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONR^4R^4$ ,  $XCONHR^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,  $XNH_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,  $XNHSO_2R^4$ ,  $XN(SO_2R^4)SO_2R^4$ ,  $XNR^4SO_2R^4$ ,  $XNHCOR^4$ ,  $XNHCOOR^4$ ,  $XNHCONHR^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $R^4$ ;
- $R^2$  is a monocyclic or bicyclic  $C_{6-10}$  aryl group which is unsubstituted or is substituted with up to three of the following substituents, independently of one another selected from:
- F, Cl, Br, I,  $XOH$ ,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOHR^4)$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ ,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONHR^4$ ,  $XCONR^4R^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,  $XNHSO_2R^4$ ,  $XN(SO_2R^4)SO_2R^4$ ,  $XNR^4SO_2R^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $R^4$ ;
- $R^3$  is one or two substituents which are independently of one another selected from:
- hydrogen, F, Cl, Br, I,  $XOH$ ,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,  $XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOHR^4)$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ ,  $XCN$ ,  $XCOOH$ ,  $XCOOR^4$ ,  $XCONH_2$ ,  $XCONHR^4$ ,  $XCONR^4R^4$ ,  $XCONHOH$ ,  $XCONHOR^4$ ,  $XCOSR^4$ ,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,  $XNH_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,  $XNHSO_2R^4$ ,  $XNR^4SO_2R^4$ ,  $XN(SO_2R^4)(SO_2R^4)$ ,  $XNHCOR^4$ ,  $XNHCOOR^4$ ,  $XNHCONHR^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $R^4$ ;
- $R^4$  and  $R^4$ , independently of one another, are each  $C_{1-4}$  perfluoroalkyl,  $C_{1-6}$  alkyl,  $C_{2-6}$

- alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-3</sub> alkyl-C<sub>3-7</sub> cycloalkyl, C<sub>1-3</sub> alkyl-C<sub>6-10</sub> aryl, or C<sub>6-10</sub> aryl, wherein aryl groups are unsubstituted or substituted by one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub>,
- R<sup>5</sup> and R<sup>5'</sup>, independently of one another, are each C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl, wherein in each case a carbon atom is optionally replaced by O, S, SO, SO<sub>2</sub>, NH, N C<sub>1-3</sub> alkyl or N C<sub>1-3</sub> alkanoyl, C<sub>3-7</sub> cycloalkyl-C<sub>0-3</sub> alkyl, or C<sub>6-10</sub> aryl;
- A is C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, or (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), wherein in the alkanediyl, alkenediyl, and alkinediyl groups a carbon atom or two carbon atoms are optionally replaced by O, NH, NC<sub>1-3</sub> alkyl, or NC<sub>1-3</sub> alkanoyl, and wherein alkanediyl and cycloalkanediyl groups are optionally substituted with up to two substituents selected from =O, OH, OC<sub>1-3</sub> alkyl, NH<sub>2</sub>, NHC<sub>1-3</sub> alkyl, NHC<sub>1-3</sub> alkanoyl, N(C<sub>1-3</sub> alkyl)<sub>2</sub>, and N(C<sub>1-3</sub> alkyl)(C<sub>1-3</sub> alkanoyl); and
- B is COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHNH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>5</sup>, SO<sub>2</sub>NR<sup>5</sup>R<sup>5'</sup>, PO<sub>3</sub>H, PO(OH)(OR<sup>5</sup>), PO(OR<sup>5</sup>)(OR<sup>5'</sup>), PO(OH)(NHR<sup>5</sup>), or PO(NHR<sup>5</sup>)(NHR<sup>5'</sup>), in each case bonded to a carbon atom of group A, or the entire group Y-A-B is N(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>) or NHSO<sub>2</sub>R<sup>4</sup>.
33. (Currently Amended) A method according to claim 15, wherein said patient is suffering from ~~neuro-inflammation~~ neuroinflammation.
34. (Previously Presented) A method according to claim 15, wherein said patient is suffering from a stroke.
35. (Previously Presented) A method according to claim 32, wherein said compound is 6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy] hexanoic isopropyl ester.

36. (Previously Presented) A method according to claim 32, wherein said compound is  
6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy] hexanoic isopropyl ester.
37. (Currently Amended) A method according to claim 15, wherein said patient is suffering from ~~neurohal~~ neuronal dysfunction or degeneration.
38. (Currently Amended) A method according to claim 15, wherein said patient is suffering from ~~neurohal~~ Alzheimer's disease.
39. (Cancelled)
40. (Previously Presented) A method for treating a patient suffering from a disease associated with microglia activation comprising administering to said patient an effective amount of a benzimidazole compound of formula II



or a physiologically compatible salt thereof,

in which

R<sup>1</sup> means a monocyclic or bicyclic C<sub>6-12</sub> aryl group, ~~wherein when said aryl group is~~ optionally substituted with up to three of the following substituents, independently of one another selected from:

F, Cl, Br, I, C(NH)NH<sub>2</sub>, C(NH)NHR<sup>4</sup>, C(NH)NR<sup>4</sup>R<sup>4'</sup>, C(NR<sup>4</sup>)NH<sub>2</sub>, C(NR<sup>4</sup>)NHR<sup>4</sup>, C(NR<sup>4</sup>)NR<sup>4</sup>R<sup>4'</sup>, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>, XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4'</sup>, XC(NO(COR<sup>4</sup>))R<sup>4'</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONR<sup>4</sup>R<sup>4'</sup>, XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4'</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>,

$\text{XNR}^4\text{R}^4$ ,  $\text{XNH}\text{SO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4)$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4$ ,  $\text{XNH}\text{COR}^4$ ,  
 $\text{XNH}\text{COOR}^4$ ,  $\text{XNH}\text{CONHR}^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-  
dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $\text{R}^4$ ,

~~wherein when two of said substituents for the aryl group are in ortho position to  
one another, they are optionally linked to one another to jointly form  
methanediylbisoxy, ethane 1,2-diylbisoxy, propane 1,3-diyl, or butane 1,4-diyl;~~

$\text{R}^2$  means a monocyclic or bicyclic  $\text{C}_{6-10}$  aryl group, ~~wherein said aryl group is~~  
optionally substituted with up to three of the following substituents, independently  
of one another selected from:

F, Cl, Br, I,  $\text{C}(\text{NH})\text{NH}_2$ ,  $\text{C}(\text{NH})\text{NHR}^4$ ,  $\text{C}(\text{NH})\text{NR}^4\text{R}^4$ ,  $\text{C}(\text{NR}^4)\text{NH}_2$ ,  $\text{C}(\text{NR}^4)\text{NHR}^4$ ,  
 $\text{C}(\text{NR}^4)\text{NR}^4\text{R}^4$ ,  $\text{XOH}$ ,  $\text{XOR}^4$ ,  $\text{XOCOR}^4$ ,  $\text{XOCONHR}^4$ ,  $\text{XOCOOR}^4$ ,  $\text{XCOR}^4$ ,  
 $\text{XC}(\text{NOH})\text{R}^4$ ,  $\text{XC}(\text{NOR}^4)\text{R}^4$ ,  $\text{XC}(\text{NO}(\text{COR}^4))\text{R}^4$ ,  $\text{XCN}$ ,  $\text{XCOOH}$ ,  $\text{XCOOR}^4$ ,  
 $\text{XCONH}_2$ ,  $\text{XCONR}^4\text{R}^4$ ,  $\text{XCONHR}^4$ ,  $\text{XCONHOH}$ ,  $\text{XCONHOR}^4$ ,  $\text{XCOSR}^4$ ,  $\text{XSR}^4$ ,  
 $\text{XSOR}^4$ ,  $\text{XSO}_2\text{R}^4$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NHR}^4$ ,  $\text{SO}_2\text{NR}^4\text{R}^4$ ,  $\text{NO}_2$ ,  $\text{XNH}_2$ ,  $\text{XNHR}^4$ ,  
 $\text{XNR}^4\text{R}^4$ ,  $\text{XNH}\text{SO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4)$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4$ ,  $\text{XNH}\text{COR}^4$ ,  
 $\text{XNH}\text{COOR}^4$ ,  $\text{XNH}\text{CONHR}^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-  
dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $\text{R}^4$ ,

~~wherein when two of said substituents for the aryl group are in ortho position to  
one another, they are optionally linked to one another to jointly form methanediyl-  
bisoxy, ethane 1,2-diylbisoxy, propane 1,3-diyl, or butane 1,4-diyl;~~

$\text{R}^3$  stands for one or two substituents which are each independently of one another  
selected from:

hydrogen, F, Cl, Br, I,  $\text{XOH}$ ,  $\text{XOR}^4$ ,  $\text{XOCOR}^4$ ,  $\text{XOCONHR}^4$ ,  $\text{XOCOOR}^4$ ,  
 $\text{XCOR}^4$ ,  $\text{XC}(\text{NOH})\text{R}^4$ ,  $\text{XC}(\text{NOR}^4)\text{R}^4$ ,  $\text{XC}(\text{NO}(\text{COR}^4))\text{R}^4$ ,  $\text{XCN}$ ,  $\text{XCOOH}$ ,  
 $\text{XCOOR}^4$ ,  $\text{XCONH}_2$ ,  $\text{XCONHR}^4$ ,  $\text{XCONR}^4\text{R}^4$ ,  $\text{XCONHOH}$ ,  $\text{XCONHOR}^4$ ,  
 $\text{XCOSR}^4$ ,  $\text{XSR}^4$ ,  $\text{XSOR}^4$ ,  $\text{XSO}_2\text{R}^4$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NHR}^4$ ,  $\text{SO}_2\text{NR}^4\text{R}^4$ ,  $\text{NO}_2$ ,  $\text{XNH}_2$ ,  
 $\text{XNHR}^4$ ,  $\text{XNR}^4\text{R}^4$ ,  $\text{XNH}\text{SO}_2\text{R}^4$ ,  $\text{XNR}^4\text{SO}_2\text{R}^4$ ,  $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}^4)$ ,  $\text{XNH}\text{COR}^4$ ,  
 $\text{XNH}\text{COOR}^4$ ,  $\text{XNH}\text{CONHR}^4$ , tetrahydro-2,5-dioxopyrrol-1-yl, or 2,5-dihydro-  
2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and  $\text{R}^4$ ,

~~wherein when two substituents R<sup>3</sup> are in ortho position to one another, they are optionally linked to one another to jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl;~~

R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean C<sub>1-4</sub> perfluoroalkyl, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-7</sub> cycloalkyl), C<sub>1-3</sub> alkyl-C<sub>6-10</sub> aryl, or C<sub>6-10</sub> aryl,

wherein the C<sub>6-10</sub> aryl groups are optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub>, or optionally carry an annelated methanediylbisoxy group or ethane-1,2-diylbisoxy group,

R<sup>5</sup> and R<sup>5'</sup>, independently of one another, mean hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl,

wherein in each case a carbon atom is optionally replaced by O, S, SO, SO<sub>2</sub>, NH, N C<sub>1-3</sub> alkyl or N C<sub>1-3</sub> alkanoyl, C<sub>3-7</sub> cycloalkyl-C<sub>0-3</sub> alkyl, or C<sub>6-10</sub> aryl,

wherein the mentioned alkyl, alkenyl and alkynyl groups are optionally substituted with one of the previously mentioned cycloalkyls or aryls,

wherein all previously mentioned alkyl and cycloalkyl radicals are optionally substituted with up to two substituents selected from CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, OH, O C<sub>1-3</sub> alkyl, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, N(C<sub>1-3</sub> alkyl)(C<sub>1-3</sub> alkanoyl), COOH, CONH<sub>2</sub>, and COO C<sub>1-3</sub> alkyl, and all previously mentioned aryl groups are optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub> or optionally carry an annelated methanediylbisoxy, or ethane-1,2-diylbisoxy group,

A means C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), or (C<sub>0-5</sub> alkanediylarylene-C<sub>0-5</sub> alkanediyl), wherein the aryl groups are optionally substituted with one or two substituents selected from F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, NO<sub>2</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, and C<sub>2</sub>F<sub>5</sub>, wherein in the mentioned aliphatic groups, one or two carbon atoms are each optionally replaced by O, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, or NSO<sub>2</sub>R<sup>4</sup>,

- and wherein alkyl or cycloalkyl groups are optionally substituted with up to two substituents selected from F, OH, OR<sup>4</sup>, OCOR<sup>4</sup>, =O, NH<sub>2</sub>, NR<sup>4</sup>R<sup>4'</sup>, NHCOR<sup>4</sup>, NHCOOR<sup>4</sup>, NHCONHR<sup>4</sup>, NHSO<sub>2</sub>R<sup>4</sup> SH, and SR<sup>4</sup>,
- B means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COR<sup>5</sup>, C(NOH)R<sup>5</sup>, C(NOR<sup>5</sup>)R<sup>5'</sup>, C(NO(COR<sup>5</sup>))R<sup>5'</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHNH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>5</sup>, SO<sub>2</sub>NR<sup>5</sup>R<sup>5'</sup>, PO<sub>3</sub>H, PO(OH)(OR<sup>5</sup>), PO(OR<sup>5</sup>)(OR<sup>5'</sup>), PO(OH)(NHR<sup>5</sup>), PO(NHR<sup>5</sup>)(NHR<sup>5'</sup>), or tetrazolyl, each bonded to a carbon atom of group A, or the entire group Y-A-B is N(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4'</sup>) or NHSO<sub>2</sub>R<sup>4</sup>,
- X means a bond, CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>, CH(CH<sub>3</sub>), (CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>2</sub>CH<sub>3</sub>), CH(CH<sub>3</sub>)CH<sub>2</sub>, or CH<sub>2</sub>CH(CH<sub>3</sub>), and
- Y means a bond, O, S, SO, SO<sub>2</sub>, NH, NR<sup>4</sup>, NCOR<sup>4</sup>, or NSO<sub>2</sub>R<sup>4</sup>.
41. (Cancelled)
42. (Currently Amended) A method for treating a patient suffering from a disease associated with chronic inflammation according to claim 15, comprising administering to said patient an effective amount of a benzimidazole compound of formula II wherein all heterocyclic groups are selected from pyridinyl, pyridyl, thienyl, imidazol, indonyl, furyl, pyrrolidin, morpholin, piperidin, and piperazine.
43. (New Claim) A method for treating a patient according to claim 33, wherein said patient is suffering from AIDS dementia, amyotrophic lateral sclerosis, Creutzfeldt-Jacob disease, Down's syndrome, diffuse Lewy body's disease, Huntington's disease, leukoencephalopathy, multiple sclerosis, Parkinson's disease, Pick's disease, Alzheimer's disease, stroke, temporary lobe epilepsy, or tumors.
43. (New Claim) A method according to claim 43, wherein said patient is suffering from multiple sclerosis.